Cortexyme Announces Get Demo of Atuzaginstat in Alzheimer’s Sickness Has Exceeded Analyze Enrollment Goal of 570 Sufferers
- Interim investigation of the Phase 2/3 Gain Trial expected to take place ahead of calendar year-end 2020 Cortexyme, Inc. (Nasdaq: CRTX) now declared that...